Skip to content

Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms

Effect of BTL-899 Device for Non-invasive Lipolysis and Improvement of Muscle Tone in Upper Arms

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04596241
Enrollment
34
Registered
2020-10-22
Start date
2020-10-05
Completion date
2022-02-10
Last updated
2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fat Disorder

Brief summary

This study will evaluate the clinical efficacy and safety of the BTL-899 device for changes in subcutaneous fat tissue and muscle tissue of arms. The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device.

Detailed description

This study will evaluate the clinical efficacy and safety of the BTL-899 device for changes in subcutaneous fat tissue and muscle tissue of arms. The study is a prospective multi-center open-label single-arm study. The subjects will be enrolled and assigned into a single study group. Subjects will be required to complete four (4) treatment visits and two follow-up visits. All of the study subjects will receive the treatment with the subject device. At the baseline visit, MRI imaging will be performed; the subject's weight and arm circumference will be recorded. Photos of the treated area will be taken. The treatment administration phase will consist of four (4) treatments, delivered 5-10 days apart. The applicator of BTL-899 will be applied over the treatment area. The device will induce visible muscle contractions along with heating of the subcutaneous fat. Each therapy session will last 30 minutes. At the last therapy visit, the subject's weight and arm circumference will be recorded, and photos of the treated area will be taken. In addition, subjects will receive a Subject Satisfaction Questionnaire to fill in. Safety measures will include documentation of adverse events (AE), including the subject's experience of pain or discomfort after each procedure. Following each treatment administration and at all of the follow-up visits, subjects will be checked for immediate post-procedure adverse event assessment. During the post-procedure visits (at 1-month and 3-month follow-up visits), the subjects will undergo a MRI imaging. Also, the subject's satisfaction will be noted, and weight with arm circumference will be recorded. Photographs of the treated area will be taken. In addition, subjects will receive a Lifestyle Change Questionnaire to fill in.

Interventions

DEVICEBTL-899

Treatment with intensities of a magnetic field and radiofrequency energy just below the patient's tolerance threshold.

Sponsors

BTL Industries Ltd.
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Arm fat layer \> 1.0 cm * Age \> 21 years * Voluntarily signed an informed consent form * BMI ≤ 35 kg/m2 * Women of child-bearing potential are required to use birth control measures during the * whole duration of the study * Subjects willing and able to abstain from partaking in any treatments other than the study procedure to promote body contouring during study participation * Subjects willing and able to maintain her regular (pre-procedure) diet and exercise regimen without affecting significant change in either direction during study participation

Exclusion criteria

* Electronic implants (such as cardiac pacemakers, defibrillators, and neurostimulators) * Metal implants * Drug pumps * Malignant tumor * Pulmonary insufficiency * Injured or otherwise impaired muscles * Cardiovascular diseases * Disturbance of temperature or pain perception * Hemorrhagic conditions * Septic conditions and empyema * Acute inflammations * Systemic or local infection such as osteomyelitis and tuberculosis * Contagious skin disease * Elevated body temperature * Pregnancy, postpartum period, nursing, and menstruation * Intrauterine device (IUD) * Swollen or neoplastic tissues, space-occupying lesions or skin eruptions in the treatment area * Basedow's disease

Design outcomes

Primary

MeasureTime frameDescription
The evaluation of structural changes of subcutaneous tissues of the of the upper arms4 monthsThe evaluation of structural changes of subcutaneous tissues between pre-treatment and post-treatment based on MRI imaging through measurements of the thickness of subcutaneous tissues
The evaluation of change in adipose layer thickness4 monthsThe evaluation of change in adipose layer thickness between pre-treatment and post-treatment based on arm circumference measurements.

Secondary

MeasureTime frameDescription
Patient's satisfaction with study treatment measured via questionnaires4 monthsTo determine the patient's satisfaction with study treatment for non-invasive lipolysis and improvement of muscle tone in upper arms. The 5-point Likert scale Satisfaction questionnaire will be used to evaluate the participant's satisfaction with the therapy outcome. Subject satisfaction will be assessed after the last therapy visit and during the follow-up visits with 4-therapy related questions with answer Strongly agree will be the best possible answer and Strongly disagree the worst.
Evaluation of the Therapy's Safety Measured Via Therapy Comfort Questionnaire4 monthsThe outcome will further be measured through the occurrence of adverse events or lack thereof. On Numerical Analog Scale (0-10), where 0 represents 'no pain' and 10 represents 'worst possible pain' select the level of pain experienced during the treatment.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026